Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

Netland, Peter A.; Landry, Theresa; Sullivan, Emily; Andrew, Russell; Silver, Lester; Weiner, Alan M.; Mallick, Sushanta; Dickerson, Jaime E.; Bergamini, Michael V.W.; Robertson, S.M.; Davis, Alberta A.

doi:10.1016/s0002-9394(01)01177-1

Cited by 392 publications

(269 citation statements)

References 10 publications

Supporting

Mentioning

235

Contrasting

Unclassified

Order By: Relevance

“…The ocular irritation finding in this survey appears to be new and not to have been noted as different among the prostaglandins in previous clinical trials. [23][24][25][26] This study suggests that patient satisfaction may be related to compliance, perceived effectiveness of the treatment, ease and convenience of use, acceptance of illness, and knowledge of glaucoma, as well as side effects. Although physicians may correctly assess patient satisfaction, they may not be able to predict patient compliance.…”

Section: Discussionmentioning

confidence: 87%

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients

Day¹,

Sharpe

Atkinson

et al. 2005

Eye

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 87%

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients

Day¹,

Sharpe

Atkinson

et al. 2005

Eye

View full text Add to dashboard Cite

“…26 In studies carried out with travoprost in the laser monkey model, reductions in IOP were observed beginning 2 h after administration and peaked by 12À20 h after dose. 8 The onset of IOP lowering of brinzolamide in the laser-treated monkey model was seen by 1 h, peak IOP lowering occurred by 3 h after dosing. 9 Although the time of onset of action and peak IOP-lowering effect of two drugs did not coincide with each other, we administered both drugs immediately after surgery in order to keep the variables to a minimum when comparing their effect on IOP.…”

Section: Discussionmentioning

confidence: 95%

“…Travoprost acid has greater affinity for prostaglandin F receptor than either prostaglandin F 2a or latanoprost acid. 8,20 The receptors are abundant in the longitudinal ciliary muscle of the human eye and iris sphincter. 20 The IOP-lowering efficacy of travoprost was found to be comparable to latanoprost and timoptic.…”

Section: Discussionmentioning

confidence: 99%

“…20 The IOP-lowering efficacy of travoprost was found to be comparable to latanoprost and timoptic. 8 Although orally administered carbonic anhydrase inhibitors suppress aqueous humour production by 20À35%, they are associated with significant side effects. 14,21 Dorzolamide was the first topical carbonic anhydrase inhibitor used for lowering IOP.…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6][7] Travoprost is a PGF 2a analogue that reduces IOP by increasing the outflow of aqueous humour through the uveoscleral pathway. 8 Brinzolamide is a topically active carbonic anhydrase inhibitor. It has high affinity and inhibitory potency against human carbonic anhydrase inhibitor-II, an isozyme found in the ciliary epithelia, which are involved with aqueous humour secretion.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification

Ermiş

Öztürk

İnan

2004

Eye

View full text Add to dashboard Cite

Purpose To evaluate the intraocular pressure (IOP) lowering effect of travoprost and brinzolamide within the first 24 h after phacoemulsification cataract surgery. Methods This prospective, randomized, double-masked, controlled study comprised 90 eyes of 90 consecutive patients with senile cataract who had uneventful phacoemulsification surgery. Eyes in the first group received travoprost 0.0015%, second group received brinzolamide 1%. Eyes in the third group received balanced salt solution and were used as control. One drop was instilled immediately after surgery. IOP was measured 24 h preoperatively, 6 and 24 h postoperatively. Analysis of variance, Student's-t and w 2 -tests were used for statistical analyses. Results Preoperatively IOP was not significantly different among the three groups (P ¼ 0.653). At 6 and 24 h postoperatively IOP was lower in both travoprost and brinzolamide group when compared to control group (P ¼ 0.018 and 0.015 at 6 h, P ¼ 0.010 and 0.012 at 24 h, respectively). The difference between travoprost and brinzolamide group was not significant (P ¼ 0.859 at 6 h and P ¼ 0.581 at 24 h). Both travoprost and brinzolamide significantly reduced IOP increases when compared to control eyes at 6 and 24 h (P ¼ 0.036 and 0.029 at 6 h, P ¼ 0.010 and 0.007 at 24 h, respectively). The difference in IOP increase at 6 and 24 h between travoprost and brinzolamide group was not significant (P ¼ 0.744 at 6 h and P ¼ 0.672 at 24 h). Conclusion Both travoprost and brinzolamide significantly lowered IOP after small incision phacoemulsification cataract surgery within the first 24 h without any side effect.

show abstract

A 5-Year, Multicenter, Open-Label, Safety Study of Adjunctive LatanoprostTherapy for Glaucoma

Alm

Schoenfelder²,

McDermott³

2004

Arch Ophthalmol

View full text Add to dashboard Cite

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

Cited by 392 publications

References 10 publications

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients

Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification

A 5-Year, Multicenter, Open-Label, Safety Study of Adjunctive LatanoprostTherapy for Glaucoma

Contact Info

Product

Resources

About